12:12 PM EDT, 07/31/2025 (MT Newswires) -- Supernus Pharmaceuticals ( SUPN ) said Thursday that it has completed its acquisition of Sage Therapeutics ( SAGE ) .

Supernus offered to pay $8.50 in cash per share of Sage Therapeutics ( SAGE ), plus one non-tradable contingent value right worth up to $3.50 per share in cash subject to the achievement of certain milestones.

The acquisition is estimated to yield up to $200 million in annual cost synergies and be accretive in 2026, Supernus said.

Shares of Supernus Pharmaceuticals ( SUPN ) were up more than 5% in recent Thursday trading.

Price: 35.08, Change: +1.52, Percent Change: +4.53